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Abstract
The generation of diversity and plasticity of transcriptional programs are key components of effective vertebrate immune
responses. The role of Alternative Splicing has been recognized, but it is underappreciated and poorly understood as a
critical mechanism for the regulation and fine-tuning of physiological immune responses. Here we report the generation of
loss-of-function phenotypes for a large collection of genes known or predicted to be involved in the splicing reaction and
the identification of 19 novel regulators of IL-1b secretion in response to E. coli challenge of THP-1 cells. Twelve of these
genes are required for IL-1b secretion, while seven are negative regulators of this process. Silencing of SFRS3 increased IL-1b
secretion due to elevation of IL-1b and caspase-1 mRNA in addition to active caspase-1 levels. This study points to the
relevance of splicing in the regulation of auto-inflammatory diseases.
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Introduction
The success of the vertebrate immune system relies on a
remarkable potential to generate highly diverse detection,
transduction and effector mechanisms in addition to the ability
of individual cells to rapidly adapt and respond to changing
environmental conditions [1]. Transcriptional regulation in the
immune system has received the most attention in recent years,
but achieving such diversity and flexibility of function requires the
operation of additional mechanisms of gene regulation. Alternative
Splicing (AS), which affects most of human genes and is altered in
at least 15% of all point mutations causing human genetic disease
[2,3], is a potential critical mechanism for the regulation and fine-
tuning of physiological immune responses [4,5].
Our genome contains much fewer coding genes than anti-
cipated before the completion of the human genome-sequencing
project [6]. Alternative splicing permits the generation of a large
array of mRNA transcripts and protein isoforms from a limited
number of genes [4,5]. By including or deleting functional protein
domains it can change many protein properties including
protein–protein interactions, subcellular localization, stability,
DNA binding, and enzymatic properties of the dominant
isoforms [7]. Two recent landmark reports estimate that 92%
to 95% of all human primary transcripts can undergo alternative
splicing [8,9]. This process seems to be especially prevalent and
functionally significant in the immune and nervous systems
[4,10].
Microorganisms activate the innate immune system using
germline-encoded pattern-recognition receptors (PRRs). Several
classes of PRRs, including Toll-like receptors, recognize distinct
microbial components and directly activate immune cells,
including antigen presentation cells such as dendritic cells (DCs).
Exposure of immune cells to the agonists of these receptors
activates the NF-kB pathway, rapidly inducing the expression of
cytokines (such as IL-1b), co-stimulatory molecules and other
effector molecules that are part of an effective immune response
[1]. This initial response is terminated several hours later through
incompletely characterized molecules and pathways [11] but that
are of critical importance to avoid an excessive NF-kB signaling.
The NF-kB transcription factor has been the subject of intense
study for many years, reflecting its importance in the immune
response. Interestingly, many components along the pathways
leading to NF-kB activation, such as MyD88, IRAK family
members, TAB1, TAK1, IkB kinase complex factors and NF-kB
transcription factors (reviewed in [5]) have been shown to undergo
induced alternative splicing in the later phase of the immune
response and to generate shorter isoforms that can act as dominant
negative factors able to shut down NF-kB dependent transcription.
Here we report the use of a subset of the TRC lentiviral human
library [12] to generate loss-of-function phenotypes for a large
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splicing reaction (425 genes), with an average 5-fold coverage [13].
By applying this library in human THP-1 monocytic cells, we aim
to systematically identify components of the splicing machinery
that modulate the secretion of IL-1b. We have identified 19 genes
that significantly affect the production of IL-1b after a 24 h
challenge with PFA-fixed E. coli. Twelve of these genes are
required for IL-1b secretion, while seven are negative regulators of
this process. We chose one of the highest scoring negative
regulators, SFRS3, for further characterization of its role in IL-1b
secretion.
Methods
Cell Culture
THP-1 cells (ATCC TIB-202) were grown in R10- RPMI
media 1640 supplemented with 10% (v/v) Fetal Bovine Serum,
1% (v/v) Penicillin-Streptomycin, 1% (v/v) Pyruvate , 1% (v/v) L-
Glutamine , 1% (v/v) Non-essential aminoacids , 1% (v/v) Hepes
buffer and 0.05 M of 2-Mercaptoethanol, HEK 293T cells
(ATCC CRL-11268) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) Fetal Bovine
Serum, 1% (v/v) Penicillin-Streptomycin and 0.05 M of 2-
Mercaptoethanol. Cells were kept at 37uC under a 5% carbon
dioxide (CO2) atmosphere. Purification of bone marrow derived
cells (BMDCs) was adapted from previously described [14,15].
Briefly, marrow cavities of the tibias and femurs of 8–12 week-old
mice were flushed with complete RPMI 1640 (10% FBS) using a
27-gauge needle (Terumo, Tokyo, Japan). After red cells
hypotonic lysis for 5 min (with ammonium chloride solution),
BM cells were washed and seeded in 96 well round bottom plates
(5610
4/well), in culture medium supplemented with 30%
conditioned medium from mouse granulocyte-macrophage colony
stimulating factor (GM-CSF) producing J558L cells. Peripheral
blood mononuclear cells (PBMCs) were isolated from buffy coats
of healthy donors by density gradient centrifugation using Ficoll-
Paque (GE Healthcare). Monocytes were magnetically isolated
from PBMCs with CD14 microbeads (Miltenyi Biotec, Germany).
The RNAi Consortium RNAi library and lentiviral infection
Detailed description of the RNAi Consortium (TRC) lentiviral
RNAi library used in this study was originally described in [13]
and [16]. Briefly, most splicing and NLR genes were targeted with
,5 short hairpin RNAs (shRNAs) expressed under the control of
the U6 Pol III promoter in a lentiviral vector (pLKO.1) that also
confers puromycin resistance. Plasmid DNA purification, lentiviral
production and infection were performed as described [12] (and
see www.broad.mit.edu/rnai/trc/lib for additional details).
IL-1b secretion assay
THP-1 cells were infected with the shRNA-expressing lentivirus
and selected using puromycin 48 hrs later. After the 3 days of
selection, plates were duplicated. One of the plates was used to
measure the cell number using Alamar Blue cell viability assay
(Invitrogen), according to manufacturer’s instructions. In the other
plate, cells were stimulated with 4% PFA-fixed DH5a E. coli at a
Multiplicity of Infection (MOI) of 20 bacterial cells per THP-1 cell.
After the indicated times, cell supernatants were collected and IL-
1b cytokine quantified by ELISA.
ELISA, qRT-PCR, IB and FACS
Cytokine concentrations in cell supernatants were assayed by
ELISA using Human IL-1 beta/IL-1F2 DuoSet (R&D Systems),
according to company’s protocol. For quantitative RT-PCR
(qRT-PCR), total RNA was extracted using TRIzol reagent
(Invitrogen) and cDNA synthesis used Superscript II Reverse
Transcriptase (Invitrogen). qRT-PCR was performed in the
presence of Power SYBR green PCR Master Mix (Applied
Biosystems) and the amplification protocol was performed
on a Rotor-Gene 6000 (Corbett). All samples were normalized
to the expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and relative expression was calculated using Pfaffl’s
method [17].
For immunoblotting (IB), cells were collected, washed twice and
lysed for 15 minutes at 4uC using RIPA buffer (50 mM Tris-HCl
at pH=7.4, 1% NP-40, 0.25% Sodium Deoxicholate, 150 mM
NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF in the presence
of proteases inhibitor cocktail (Roche)). Primary antibodies against
b-actin, caspase-1, HMGB1, NLRP3 and V5 were from Abcam;
against ASC and SFRS3 were from Abnova. Secondary antibodies
against mouse or rabbit were from Cell Signaling. Caspase-1
activity was measured using the Carboxyfluorescein FLICA
Detection kit for Caspase Assay (Immunochemistry Technologies,
LLC). Briefly, cells were incubated for 1 hour at 37uC with 306
FLICA solution at a 1:30 ratio, washed 3 times, and ressuspended
in 150 mL of wash buffer. The samples were immediately assayed
by Flow citometry, using a FACSCalibur system (BD biosciences)
and the data was analysed using FlowJo software (Tree Star Inc).
SFRS3 Overexpression
Lentiviral vector for SFRS3 protein overexpression was
constructed using the Gateway pENTR11 and pLenti6.2/V5-
DEST Gateway vectors from Invitrogen. SFRS3 was amplified
from THP-1 cells cDNA.
Data analysis
Hit identification: Values were normalized by dividing the
amount of secreted IL-1b in the conditioned media 24 hrs after E.
coli stimulation by the number of cells in each well and then by the
average concentration per cell of the plate. Results were
logarithmic natural transformed. Scores were sorted in ascending
order and graphed. We calculated 1.5 SDEVs above and below
the average and identified genes for which at least two
independent targeting shRNAs gave similar phenotypes. After
two or more rounds of phenotypic validation, we chose 30 genes
that reproducibly changed IL-1b secretion when silenced. Statistic
analysis: The data were compared using the t-student test, and
analyzed using the Prism software unless stated otherwise. All data
presented are the average of a minimum of three independent
biological replicas.
NF- kB reporter gene assay
Lentiviral particles carrying a NF-kB-responsive GFP-express-
ing reporter gene (Cignal Lenti Reporters, SABiosciences) were
used to infect THP-1 cells and to establish a stable cell line. For the
infections, 10 mL of lentiviral particles were used and the protocol
was according to the manufacturer. Once established, the THP-1
NF- kB responsive cell line was infected with lentivirus expressing
shRNAs for the specific silencing of SFRS3. For each infection,
20 mL of shRNA lentivirus were used; otherwise the protocol was
as described above, including the infectious stimulus with PFA-
fixed E. coli. The GFP fluorescence was assayed by flow cytometry
using a FACSCalibur system (BD biosciences).
Actinomycin D treatment
THP-1 cells infected with shRNA-expressing lentivirus were
stimulated at day six of infection with PFA-fixed E. coli at MOI of
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treated with 5 mg/mL of actinomycin D (ActD, AppliChem) and
incubated for 1, 2, 3 or 4 hours, after which were collected for
RNA extraction. The half-life (t1/2) of IL-1b mRNA was
determined by adjusting an exponential trendline to the data
points and using the formula t1/2=ln(2)/b (b obtained from the
exponential function y=ce
bx).
IL-1b primers
Exonic IL-1b primers: CTCGCCAGTGAAATGATGGCT
(forward) and GTCGGAGATTCGTAGCTGGAT (reverse).
Intronic IL-1b primers: TCACACGGAAAGTTGGGGGCC
(forward) and TGTGGGGCAAGGGACAAAGATG (reverse).
All other primers used in qRT-PCR were obtained from Primer
Bank http://pga.mgh.harvard.edu/primerbank/index.html.
Results
THP-1 cells secrete IL-1b in response to E. coli challenge
The sequence of events culminating in IL-1b secretion is
complex, but can be summarized in two steps: induction of pro-IL-
1b and its processing by activated caspase-1 (reviewed in [18]).
The human monocytic cell line THP-1 has been a preferred in vitro
model system to study the mechanisms of IL-1b induction and
processing [19]. To search for novel regulators of IL-1b secretion,
we begun by the development and characterization of an in vitro
assay to systematically test the role of splicing factors and
regulators of splicing in this process. Most of the available studies
have used purified pathogen associated molecular patterns
(PAMPs) to induce IL-1b message transcription and ATP for the
triggering of inflammasome activation to drive its processing
(reviewed in [20]). We have challenged THP-1 cells with LPS in
the absence of ATP over a 24 hr period. Under these conditions
we have observed no significant secretion of IL-1b (D’Almeida,
unpublished), confirming previous observations (reviewed in [21]).
However, stimulation of THP-1 cells with PFA-fixed E. coli caused
significant IL-1b mRNA induction (Figure 1A), caspase-1 activity
(Figure 1B) and IL-1b secretion (Figure 1C), in a range of
concentrations comparable to previous reports [22].
Stimulation of THP-1 cells with PFA-fixed E. coli caused a dramatic
increase in IL-1b mRNA expression as measured by qRT-PCR
(Figure 1A). Upon challenge, the levels of IL-1b mRNA rose quickly
and peaked at 4 hr after which they remained high for the duration of
the assay. We have used ELISA to measure the concentrations of IL-
1b in the corresponding conditioned media. IL-1b secretion can be
detected already at 2 hr after bacterial challenge, but we observe a
major increase at 4 hr, after which the concentration of IL-1b steadily
increases and only stabilizes at 48 hr after stimulation (Figure 1C and
Figure 1. THP-1 cells induce and secrete IL-1b in response to E.
coli stimulation. (A) THP-1 cells were challenged with PFA-fixed E. coli
at a 20 bacteria: 1 cell ratio. IL-1b mRNA expression was quantified by
qRT-PCR; (B) Caspase-1 activity as measured by FACS using fluorescent
caspase-1 substrate (FLICA); (C) In the same conditions, cell conditioned
media was collected and the concentration of IL-1b measured by ELISA;
(D) Caspase-1 dependent IL-1b secretion at 24 hrs after E. coli challenge
is shown by using caspase drug inhibitors; (E) and by measuring IL-1b
secretion from cells where caspase-1 was depleted by RNAi; (F)
validation of caspase-1 silencing using immunoblotting; (G) Effect of
NLRP3 and ASC in IL-1b secretion after 24 hrs of E. coli challenge; (H)
Validation of NLRP3 and ASC knockdowns, by immunoblotting using
specific antibodies against these inflammasome components; (I) the
secretion of IL-1b was compared in THP-1 cells that were stimulated
with PFA-fixed E. coli with cells that in addition to E. coli stimulation
were treated with either ATP or the P2X7 inhibitor, KN-62.
doi:10.1371/journal.pone.0019829.g001
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FACS using a caspase-1 fluorescent substrate that irreversibly binds to
its catalytic site, progressively increases after E. coli challenge and peaks
at 4 hrs after which it remains stable, with a modest increase after
12 hrs (Figure 1B).
Most of the IL-1b processing activity is mediated by caspase-1,
but other proteases can play a role (reviewed in [23]). In our
system, most of the IL-1b processing activity is accomplished by
caspase-1. In fact, broad caspase inhibitors (Z-VAD and Z-DEVD)
and the more specific caspase-1 inhibitor Z-YVAD almost
completely block the secretion of IL-1b (Figure 1D). In addition,
the specific depletion of caspase-1 from THP-1 cells using RNAi
has a similar effect (Figure 1E and F). Together, the drug and
RNAi inhibition of caspase-1 results, show caspase-1-dependent
secretion of IL-1b, in our assay.
To identify the dominating inflammasome components driving
IL-1b secretion in our assay, we have performed a small-scale
screen covering most of the NLR and CARD domain containing
proteins. We found roles for several inflammasome components
that significantly affect IL-1b secretion after 24 hr of E. coli
challenge. Silencing of NLRP3 and ASC caused the strongest
phenotypes (Figure 1G, and Moura-Alves, unpublished). The
depletion of NLRP3 and ASC were validated at the protein level
using immunoblotting (Figure 1H).
Previous studies have documented the requirement for ATP in
the processing and secretion of IL-1b [24]. However, we observe
high levels of secretion of IL-1b without addition of exogenous
ATP to E. coli challenged THP-1 cells (Figure 1C). To check if the
addition of ATP is critical in our system, we supplied ATP to E. coli
challenged THP-1 cells, but found only a marginal increase in the
level of secreted IL-1b (Figure 1I). Interestingly, by using a known
inhibitor of the purinergic receptor P2X7 (KN-62) [25], we
observed a significant decrease in the concentration of secreted IL-
1b (Figure 1I). We conclude that ATP is required for the
processing and secretion of IL-1b in our assay, but that its
exogenous supply is not necessary, because it is available in culture
possibly resulting from a small percentage of dying cells in
response to E. coli challenge or active secretion which can activate
THP-1 cells in an autocrine way [26].
An shRNA-based screen identifies splicing factors and
regulators of splicing with a role in IL-1b secretion
To identify splicing regulators with a role in IL-1b secretion by
THP-1 cells after E. coli challenge, we used a subgenomic library
targeting 425 genes (Supplementary Table S1) that was recently
used successfully for the identification of hnRNPLL as a master
regulator of CD45 alternative splicing [13]. This subset of the
RNAi Consortium (TRC) library (www.broad.mit.edu/rnai/trc/
lib) is enriched on splicing factors (SFs) and regulators of splicing
and has been assembled based on reported proteomic, bioinfor-
matics and genetic studies for splicing factor identification and
spliceosome composition characterization [27,28,29,30,31]. A
complete list of the targeted SFs can be found in supplementary
materials.
THP-1 cells were infected with lentivirus particles expressing
individual short hairpin RNAs (shRNAs) and selected with
puromycin 48 hrs later. Six days after infection, cells were split
into two plates. One was used to measure the number of cells. All
wells with less than 10.000 cells were excluded from analysis,
because we found that bellow this cut-off there is high variability in
cytokine secretion with different bacterial amounts (data not
shown). In the other plate, cells were stimulated with PFA-fixed E.
coli at a ratio of 20 bacteria per cell. ELISA was used to measure
the resulting concentrations of IL-1b in the conditioned media
24 hrs after E. coli stimulation. The concentrations of IL-1b were
divided by the number of cells in each well and again divided by
the mean concentration per cell of the plate. Increases and
decreases in relation to plate average are better identified from a
log transformation of normalized (N) values that appropriately fits
the data points in a linear relationship [32]. Accordingly, we did a
logarithmic natural transformation and graphed the sorted scores
in ascending order (Figure 2A). To quantify the deviation of
cytokine levels from the mean of all measurements within the same
plate, we calculated 1.5 SDEVs above and below the mean and
identified genes for which at least two independent targeting
shRNAs gave similar phenotypes. After two or more rounds of
phenotypic validation, we chose 30 genes that reproducibly
changed IL-1b secretion when silenced. Twenty genes decreased
the levels of IL-1b secretion when silenced (positive regulators),
while 10 led to significant increase of IL-1b secretion after
depletion (negative regulators).
We then used qRT-PCR to correlate the efficacy of knockdown
with the phenotypes observed. For 19 out of the 30 initial
candidates we found a good correlation between the best two
shRNAs in each gene and the degree of knockdown for the same
hairpins (Figure 2C). Twelve of the validated genes are positive
regulators (Table 1) and seven are negative regulators (Table 2).
Selection and validation of SFRS3 as a novel negative
regulator of IL-1b secretion
We found the High Mobility Group Box 1 (HMGB1) gene as a
positiveregulator ofIL-1bsecretion (Figure 2B). HMGB1was included
in the group of genes with a documented or possible role in splicing to
test in our assay because it was identified in one of the proteomic
studies of the spliceosome used to assemble the SF collection [27].
While its role in splicing has not been addressed, its identification in
our study supports the power of our approach because HMGB1 has a
well-documented role in the inflammatory response (reviewed in [33])
and was previously shown to regulate IL-1b secretion by the
transactivation of its promoter [34]. We did a kinetic study of IL-1b
secretion in THP-1 cells where HMGB1 was depleted and compared
it to the results for the control cells treated with the control shRNA
(shScram) and observed a strong decrease in the amount of IL-1b
secreted per cell at 24 hrs after E. coli stimulation (Figure 3A). The
shRNA tested was chosen after validating the knockdown of HMGB1
at the protein level using immunoblotting (Figure 3B).
Effective down-modulation of immune responses is critical for
physiological immune responses and to avoid autoimmunity and
autoinflammatory diseases such as those caused by deregulated
increased secretion of IL-1b due to inflammasome hyper-activation
[35]. Termination of a signal can be as important as its initiation.
However, negative feedback pathways are much less well
understood in immune signaling. We therefore decided to choose
one of the identified negative regulators in our screen to further
characterize its role in IL-1b secretion. SFRS3 was one of the
candidates that showed the strongest and most consistent
phenotype. Silencing of SFRS3 in the original primary screen by
3 independent shRNA constructs led to increase in the levels of
secreted IL-1b above the defined cut-off. After phenotypic
validation with independently produced batches of lentiviruses, we
then correlated the levels of SFRS3 silencing at the protein level
with the observed phenotypes for each construct (Figure 3C).
Construct #2 produced the best silencing, but also caused elevated
cell death possibly reflecting the essential role of SFRS3. We
therefore did not include it in Figure 3C. From the plot we can
clearly see that the level of SFRS3 depletion correlated with the
strength of the phenotype (Figure 3C). We conclude that SFRS3
silencing is the target responsible for the increase in secreted IL-1b.
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required for constitutive pre-mRNA splicing but also regulate
alternative splice site selection in a concentration-dependent
manner in addition to other documented roles in transcription,
nucleo-cytoplasmic transport and translation (reviewed in [36]).
Kinetic studies of IL-1b secretion in SFRS3 knockdown cells
compared with cells treated with the shRNA control (Figure 3D)
after the identification and validation of the best shRNA targeting
SFRS3 (Figure 3C and E) show that already at 4 hrs after E. coli
challenge there is an increase in cytokine secretion and that the
difference becomes more pronounced at 8 hrs and reaches a
maximum at 24 hrs post-challenge (Figure 3D).
To further validate the role of SFRS3 as a novel regulator of IL-
1b secretion, we took three approaches: (1) test the role of SFRS3
in IL-1b secretion in mouse cells; (2) over-expression of SFRS3 in
THP-1 cells; and (3) depletion of SFRS3 in THP-1 cells using the
drug digoxin [37].
We have used 5 independent constructs to silence SFRS3 in
bone marrow-derived dendritic cells (BMDCs). Two of them (#1
and #2) caused high levels of cell death. Using qRT-PCR to
measure the percentage of SFRS3 mRNA left in BMDCs after
treatment with constructs #3, #4 and #5, we observed an
excellent correlation with the increase in the amount of secreted
IL-1b after bacterial challenge of BMDCs (Figure 3F).
In accordance with the identified negative regulator phenotype,
we would expect that the over-expression of SFRS3 would either
produce no change in the levels of IL-1b secretion or, more
convincingly, decrease cytokine secretion. In fact, over-expression
of SFRS3 causes a dramatic decrease in the levels of IL-1b
secretion after 24 hrs of THP-1 cell challenge with PFA-fixed
Figure 2. Identification and validation of novel splicing factors with a role in IL-1b secretion. (A) THP-1 cells were infected with shRNA
expressing lentiviruses in a 96-well plate format. After puromycin selection, the number of cells was measured and stimulated with PFA-fixed E. coli.
Values of secreted IL-1b were normalized by dividing the amount of IL-1b in the conditioned media 24 hrs after E. coli stimulation by the number of
cells in each well and then by the average concentration per cell of the plate. Results were logarithmic natural transformed. Scores were sorted in
ascending order and graphed; (B) Phenotypes for 12 positive regulators and 7 negative regulators of IL-1b secretion are shown in comparison to
shScram control; (C) Validation of candidates by measurement of mRNA levels after silencing using qRT-PCR.
doi:10.1371/journal.pone.0019829.g002
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immunoblotting with an antibody against the V5 tag that was
fused to this factor (Figure 3H).
In a complementary approach, we used the recently identified
depletion effect of digoxin on SFRS3 [37], to independently test
the role of this SF on IL-1b secretion. We can show that increasing
concentrations of digoxin, starting at 50 nM, directly correlate
with increased amounts of IL-1b in THP-1 cell conditioned media
after 24 hrs of E. coli stimulation (Figure 3I). Interestingly, we start
observing depletion of SFRS3 with digoxin concentrations above
50 nM, which peaks at 200 nM (Figure 3J) after which we observe
toxic effects to the cells (data not shown).
SFRS3 mRNA and protein levels are regulated in
monocytes in response to E. coli stimulation
Expression levels of another member of the SR protein family,
SFRS1, are modulated by pro-inflammatory stimuli and in
autoimmunity [38]. We tested the regulation of the levels of
SFRS3 mRNA and protein in response to bacteria. To monitor
SFRS3 mRNA and protein levels after an E. coli challenge in
primary cells that are directly relevant for in vivo human
production of IL-1b in health and disease, we used freshly isolated
monocytes from PBMCs of volunteers and challenged them with
PFA-fixed E. coli. We found that SFRS3 mRNA was decreased
after 2 hrs of stimulation and that this tendency was more
preeminent at 4 and 8 hrs post-challenge (Figure 3L). At 24 hrs,
we observed an increase, suggesting a recovery of its levels at later
periods (Figure 3L). At the protein level, we observed a compatible
trend with delayed kinetics (Figure 3M). The decrease of SFRS3 is
evident at 4 hrs and the protein levels remain low at 24 hrs after
stimulation (Figure 3M). While similarly robust regulation was not
observed in THP-1 cells, our reproducible findings in primary
monocytes suggest that SFRS3 might play a physiologic role in the
secretion of IL-1b, and that its down-regulation might be required
for stronger caspase-1 activation.
SFRS3 silencing increases IL-1b mRNA and active
caspase-1 levels
The secretion of bioactive IL-1b is a two-step process. The first
is the induction of pro-IL-1b that starts with the NF-kB dependent
transcription of IL-1b mRNA. The second is the processing of the
inactive 31 kDa pro-molecule by activated caspase-1.
The activation of the NF-kB pathway usually starts with the
engagement of a TLR receptor, while the second step follows
inflammasome activation, which can be initiated by the
activation of the purinergic P2X7 receptor in response to the
presence of ATP (reviewed in [20]). To understand the
mechanism of regulation of IL-1b secretion by SFRS3, we
silenced SFRS3 and studied its kinetic effect on the levels of IL-
1b mRNA (Figure 4A), IL-8 mRNA (Figure 4B), caspase-1
mRNA (Figure 4C) and resulting caspase-1 activity at 24 hrs
(Figure 4D).
Table 2. IL-1b secretion candidate negative regulator genes.
Gene ID Symbol Description / Role
10399 GNB2L1 Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1
4236 MFAP1 Microfibrillar-associated protein 1
10450 PPIE Catalyze the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerate the folding of proteins.
6421 SFPQ Transcription and RNA processing.
6426 SFRS1 Serine/arginine-rich (SR) splicing factor. Modulates splice site selection.
6428 SFRS3 Serine/arginine-rich (SR) splicing factor. Modulates splice site selection.
80312 TET1 Epigenetic regulation by modification of 5 mC to hmC
doi:10.1371/journal.pone.0019829.t002
Table 1. IL-1b secretion candidate positive regulator genes.
Gene ID Symbol Description/Role
10659 Celf2 Pre-mRNA alternative splicing and may also be involved in mRNA editing, and translation
55280 CWF19L1 NA
79039 DDX54 Translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly.
9785 DHX38 Translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly.
8661 EIF3A Eukaryotic translation initiation factor 3, subunit A
3146 HMGB1 High-mobility group box 1
4670 HNRNPM Pre-mRNA processing and other aspects of mRNA metabolism and transport
8570 KHSRP Transcription, alternative pre-mRNA splicing, and mRNA localization.
8106 PABPN1 Polymerization of poly(A) tails on the 39 ends of eukaryotic genes
10946 SF3A3 Pre-mRNA splicing
140890 SFRS12 Serine/arginine-rich (SR) splicing factor. Modulates splice site selection.
23091 ZC3H13 NA
doi:10.1371/journal.pone.0019829.t001
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IL-1b (Figure 4A) and IL-8 mRNA (Figure 4B) which is especially
significant at 24 hrs after E. coli stimulation. The knockdown of
SFRS3 also increases the levels of caspase-1 mRNA, most
preeminently at 24 hrs after challenge (Figure 4C). The increase
in caspase-1 mRNA translates in an ,2.5-fold increase in the
levels of active caspase-1 at 24 hrs after stimulation, as measured
by FACS using a caspase-1 fluorescent substrate (Figure 4D). We
notice that the increase in caspase-1 mRNA and activity at 24 hrs
in SFRS3 knockdowns correlates well with the highest difference
Figure 3. Validation of SFRS3 as a novel regulator of IL-1b secretion. (A) Kinetics of IL-1b secretion in HMGB1 KD cells after E. coli stimulation
in comparison to the shScram control; and (B) validation of HMGB1 KD by immunoblotting; (C) SFRS3 protein left after SFRS3 silencing in THP-1 cells
is plotted against the phenotype for each construct as measured by IL-1b secretion, construct #2 is not shown because most cells died; (D) Secretion
of IL-1b in SFRS3 KD cells after E. coli stimulation in comparison to the shScram control; and (E) validation of SFRS3 KD by immunoblotting; (F) SFRS3
mRNA left after SFRS3 silencing in mouse bone marrow-derived dendritic cells is plotted against the phenotype for each construct as measured by IL-
1b secretion, constructs #1 and #2 are not shown because most cells died; (G) IL-1b secretion after E. coli stimulation in THP-1 cells over-expressing
SFRS3; and (H) validation of SFRS3 over-expression by immunoblotting using a specific antibody against the V5 tag; (I) IL-1b secretion by THP-1 cells
after 24 hrs of E. coli challenge in the presence of growing concentrations of the SFRS3 depleting drug digoxin; (J) validation of SFRS3 depletion by
immunoblotting using a specific antibody against SFRS3. SFRS3 levels are down modulated in monocytes in response to an E. coli challenge. (L)
Kinetics of SFRS3 mRNA expression in monocytes purified from Human PBMCs after E. coli stimulation; (M) SFRS3 protein levels in the same
conditions, by immunoblotting using a specific antibody against SFRS3.
doi:10.1371/journal.pone.0019829.g003
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secretion (Figure 3C). We conclude that SFRS3 depletion affects
and increases the activity of both steps required for IL-1b
secretion. As a control, we also looked at the effect of silencing
HMGB1 on IL-1b mRNA levels. As expected, we observed
significant and progressive differences in the levels of IL-1b
mRNA, which is decreased in HMGB1 knockdown (Figure 4E).
SFRS3 negatively regulates IL-1b transcription
The results described in the previous section suggest that the
silencing of SFRS3 could affect the level of IL-1b transcription. To
directly test this hypothesis, we have used exonic and intronic
primers to compare the levels of mRNA induction in control
(shScram) and SFRS3-silenced cells (shSFRS3) after E. coli
challenge as measured by qRT-PCR. We could observe that the
shSFRS3 to shScram ratios of IL-1b mRNA were similar when
using either exonic or intronic primers (Figure 5A), suggesting that
in fact silencing SFRS3 increases the level of IL-1b transcription.
Post-transcriptional control mechanisms have been shown to
affect the expression of pro-inflammatory mediators by regulating
the stability and translation of the mRNAs encoding them
(reviewed in [39]). To test for possible additional effects of SFRS3
at the level of the regulation of IL-b mRNA stability, we
challenged THP-1 cells with PFA-fixed E. coli for 2 hrs that were
infected with either the shRNA control or the shRNA targeting
SFRS3. Cells were then treated with Actinomycin D to inhibit
transcription and the levels of mRNA for IL-b (Figure 5B) were
monitored by qRT-PCR at the indicated time points. Based on the
results we have calculated the half-life of IL-b mRNA in control
and SFRS3-silenced THP-1 cells. In three independent experi-
ments, of which we show one representative experiment in
Figure 5B, we did not observe a significant change in the half-life
of IL-b mRNA caused by silencing of SFRS3, and therefore
conclude that the observed phenotype is mostly due to changes in
IL-b at the transcriptional level.
The transcription of IL-1b is mostly dependent on activation of
the NF-kB pathway. To compare NF-kB activation, in response to
E. coli challenge, in control THP-1 cells with those where SFRS3
was silenced, we created an NF-kB reporter cell line by stably
infecting THP-1 cells with a commercial lentiviral GFP reporter
under the control of a minimal CMV promoter and tandem
repeats of the NF-kB transcriptional response element (TRE).
Surprisingly, silencing of SFRS3 in this cell line (Figure 5C,D and
E) did not change the levels of GFP reporter expression after
treatment with PFA-fixed E. coli as compared to the shScram
treated cells.
Discussion
Alternative splicing plays an important role in the regulation of
NF-kB activation by generating different isoforms for key signaling
components along this pathway [5]. Using a lentiviral-based
system to express shRNA we were able to generate loss-of-function
phenotypes for most of the previously identified factors with a
known or putative role in splicing. In our screen, we have
validated 19 novel regulators of IL-1b secretion by THP-1 cells
after challenge with E. coli. Twelve of these are positive regulators
(secretion decreases when they are silenced), while seven are
negative regulators (secretion increases when they are silenced).
We likely did not identify several important regulators of this
process either because in some cases the knockdown was not
effective enough to reveal a phenotype or because we have
silenced genes that are involved in constitutive splicing and are
essential for cell viability. The identification of HMGB1, a well-
known DAMP (Damage-associated molecular pattern) with a
documented role in the activation of the IL-1b promoter [34],
validates our capacity to discover essential regulators, even if
HMGB1 is not a canonical splicing factor.
We chose SFRS3, a well characterized splicing factor that
belongs to the SR family, mostly because the phenotype was very
strong and consistent for 3 out of the 5 constructs used to target the
gene, but also because it was a negative regulator of IL-1b
secretion. The fact that the levels of SFRS3 are down-regulated in
human monocytes by an E. coli challenge and that another
member of the SR family of splicing factors identified in our screen
is down-modulated in inflammatory conditions [38] points to these
factors as important players in the modulation of IL-1b secretion
and activity. Immune responsive cells have evolved negative
regulatory mechanisms that function at multiple levels to
effectively terminate an immune response and to prevent excessive
host damage. However, the molecular mechanisms involved in
terminating pro-inflammatory signals are incompletely understood
Figure 4. SFRS3 depletion increases IL-1b mRNA and active
caspase-1 levels. (A) Comparison of the kinetics of IL-1b mRNA
induction after E. coli challenge in SFRS3 depleted cells and control
interfered THP-1 cells; (B) Comparison of the kinetics of IL-8 mRNA
induction after E. coli challenge in SFRS3 depleted cells and control
interfered THP-1 cells; (C) the same for caspase-1 mRNA; and (D)
measurement of active caspase-1 by FACS using fluorescent caspase-1
substrate (FLICA); (E) Kinetics of IL-1b mRNA induction after E. coli
challenge in HMGB1 depleted THP-1 cells.
doi:10.1371/journal.pone.0019829.g004
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negative regulator to further explore its mechanistic role in the
regulation of IL-1b secretion.
While we still do not understand the fine molecular mechanisms
that explain the role of SFRS3 in IL-1b secretion, it is clear that the
phenotype results from a combination of the negative regulation in
both IL-1b and caspase-1 mRNA levels which ultimately translates
into significantly higher levels of pro-IL-1b and active caspase-1 to
process it. By comparing the ratios of mRNA levels in SFRS3-
silenced to control THP-1 cells, using either exonic or intronic
primers directed to IL-1b, we could observe that they are similar,
and therefore could conclude that transcription is the most affected
step by silencing of SFRS3. To confirm that increased transcription
is the dominant step responsible for the increased levels of IL-1b
mRNA in SFRS3 silenced cells, we studied the stability of IL-1b in
control and SFRS3 silenced cells after E. coli challenge and
ActinomycinDtreatmentand foundnosignificantdifferences inthe
half-life of IL-1b in both cases.
The transcription of IL-1b depends on the activation of the NF-
kB pathway. Because its mRNA is increased in E. coli challenged
THP-1 cells where SFRS3 was silenced, we hypothesized that the
NF-kB pathway was more active in SFRS3 depleted cells.
However, SFRS3 silencing does not change the expression of a
GFP reporter under an NF-kB responsive promoter. This result
suggests that other transcription factors that are known to have a
role in IL-1b transcription, such as AP-1 or the more recently
uncovered SORY and ATF7 transcription factors [40], are
possible candidates to be affected by SFRS3.
The use of unbiased high-throughput methods such as splicing-
sensitive arrays alone or in combination with RNAseq, to compare
Figure 5. SFRS3 regulates IL-1b transcription in the context of unchanged NF- kB reporter activity. (A) IL-1b mRNA as determined using
exonic or intronic primers after 8 hours of E. coli challenge. One representative experiment is shown; (B) Plot begins after 2 hours of E. coli challenge.
Time on the x-axis indicates the period of Actinomycin D treatment. One representative experiment is shown. On the right, phenotypic control
for this experiment as measured by IL-1b secret ion is shown (triplicates with standard deviations are shown for three independent measurements);
(C, D, E) three independent experiments of NF-kB reporter activation on control or SFRS3 shRNA treated cells as measured by FACS and expressed in
Mean Fluorescence Intensity (MFI). For each figure/experiment, triplicates with standard deviations are shown for three independent measurements
and one representative measure for each sample is plotted bellow.
doi:10.1371/journal.pone.0019829.g005
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SFRS3 treated cells, are likely to help identifying the molecular
target(s) of SFRS3 which might be the direct effectors mediating
the negative regulator phenotype of SFRS3 in the secretion of IL-
1b. This line of research would be based on the assumption that
SFRS3 is a key factor for the correct splicing of a direct negative
regulator of IL-1b transcription.
In these study we have identified 19 novel regulators of IL-1b
secretion, pointing to the relevance of splicing in the regulation of
auto-inflammatory diseases, and other conditions that are
associated with over-production of this pro-inflammatory cytokine.
Further studies will determine the roles of SFRS3 and other factors
in the control of IL-1b secretion.
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